Free Shipping for Orders Over $100!

Boluoke Lumbrokinase by Canada RNA - 120 capsules Oral Supplement Canada RNA
Boluoke Lumbrokinase by Canada RNA - 120 capsules Oral Supplement Canada RNA
Boluoke Lumbrokinase by Canada RNA - 120 capsules Oral Supplement Canada RNA

- Practitioner Product -

Boluoke® Lumbrokinase | RNA Supplement - 120 capsules

Vendor
Canada RNA
Regular price
$167.98
Sale price
$167.98
Tax included. Shipping calculated at checkout.
Quantity must be 1 or more

- Practitioner Product -

Boluoke® (lumbrokinase) is an extensively researched oral enzyme that shows encouraging results for supporting healthy coagulation/fibrinolysis in the body.*

Boluoke® may assist people with a tendency towards hypercoagulation, by reducing fibrinogen and fibrin without interfering with the clotting cascade.* Boluoke® does not impact INR or aPTT, and is therefore compatible with Coumadin® or heparin.

Lumbrokinase is more potent than other enzymes on the market, including nattokinase. Boluoke® lumbrokinase is of superior quality, standardized against urokinase and t-PA, unlike other products. 

When selecting a lumbrokinase product, it’s crucial to compare the amount of active lumbrokinase per capsule, not capsule weight. Boluoke®’s capsules are 200mg, and contain 20mg of active lumbrokinase inside each capsule. It’s unlikely you’ll find another product that specifies the active ingredient and matches this ratio.

Although earthworm extract has become more commonly available, most imitations contains very little pure lumbrokinase.

Boluoke® Research

Boluoke® is the only extensively researched oral fibrinolytic supplement available. Research has included in vitro (outside the body), animal studies, toxicity studies and pharmacokinetic studies. In addition, Boluoke® has been assessed via all phases of clinical trial in China and is now used in hospitals in China, as well as being covered by the Chinese National Fundamental Health Insurance. 

Are there any side effects?

A trial involving 16 hospitals and 1560 patients in China reported no hemorrhage or major side effects. In terms of minor adverse effects, 0.19% of participants experienced a skin rash, 1.15% nausea or diarrhea, and 0.58% skin itching, with an overall adverse reaction rate of 1.92%. This research specifically applies to Boluoke® and cannot be applied to other products on the market, despite the claims.


*These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any diseases.